Metraipolis › archive › dc_e2e15e19b044

EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling — Europe PMC PMID:41154625

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41154625
DOI
10.3390/biom15101396
License (as archived)
solo-consultazione
Archived
2026-11-09T15:13:48.382Z
SHA-256 of the archived text
ba639e2e4f8ac83c961c4f6a436263b9a0b6cfe7c66a084976191b16108a87d5
Stable URL of this page
https://metraipolis.com/documento/dc_e2e15e19b044

How to cite

EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling — Europe PMC PMID:41154625 — Europe PMC (en), https://europepmc.org/article/MED/41154625 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e2e15e19b044 (Metraipolis archive dc_e2e15e19b044, sha256 ba639e2e4f8ac83c961c4f6a436263b9a0b6cfe7c66a084976191b16108a87d5)
BibTeX
@misc{dce2e15e19b044,
  title = {EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling — Europe PMC PMID:41154625},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41154625},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e2e15e19b044; sha256 ba639e2e4f8ac83c961c4f6a436263b9a0b6cfe7c66a084976191b16108a87d5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41154625. Agents can read the archived copy with the MCP tool read_document.